Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity.
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023 07 11; 7(13):3284-3296.